Cyclic protein tyrosine kinase inhibitors
AssigneeBristol-Myers Squibb Company
InventorsJagabandhu Das, Ramesh Padmanabha, Ping Chen, Derek J. Norris, Arthur M. P. Doweyko, Joel C. Barrish, John Wityak, Louis J. Lombardo, Francis Y. F. Lee
Life of this patent
Estimating the term…
Abstract
Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.
Claims27
A method for the treatment of a cancer comprising administering to a subject in need thereof an effective amount of the compound of formula III or a salt thereof:
- wherein:
- each R1, R3 and R4 is, independently, a heterocyclic group or an aryl group, optionally substituted with one or more substituents;
- and
- R2 is hydrogen or alkyl;
- wherein the cancer is chronic myelogenous leukemia (CML), gastrointestinal stromal tumor (GIST), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), ovarian cancer, melanoma, mastocytosis, germ cell tumors, acute myelogenous leukemia (AML), pediatric sarcomas, breast cancer, colorectal cancer, pancreatic cancer, or prostate cancer.
A method for the treatment of a cancer comprising administering to a subject in need thereof an effective amount of a compound of formula IV:
- wherein the cancer is chronic myelogenous leukemia (CML), gastrointestinal stromal tumor (GIST), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), ovarian cancer, melanoma, mastocytosis, germ cell tumors, acute myelogenous leukemia (AML), pediatric sarcomas, breast cancer, colorectal cancer, pancreatic cancer, or prostate cancer.
A method for the treatment of a cancer comprising administering to a subject in need thereof an effective amount of a therapeutic agent and an effective amount of a compound of formula III:
- wherein:
- each R1, R3 and R4 is, independently, a heterocyclic group or an aryl group, optionally substituted with one or more substituents;
- and
- R2 is hydrogen or alkyl;
- wherein the cancer is chronic myelogenous leukemia (CML), gastrointestinal stromal tumor (GIST), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), ovarian cancer, melanoma, mastocytosis, germ cell tumors, acute myelogenous leukemia (AML), pediatric sarcomas, breast cancer, colorectal cancer, pancreatic cancer, or prostate cancer.
A method for the oral treatment of cancer comprising administering to a subject in need thereof an effective amount of the compound of formula IV or a salt thereof:
- wherein the cancer is chronic myelogenous leukemia (CML).
A method for the oral treatment of cancer comprising administering to a subject in need thereof an effective amount of the compound of formula IV or a salt thereof:
- wherein the cancer is gastrointestinal stromal tumor (GIST).
A method for the oral treatment of cancer comprising administering to a subject in need thereof an effective amount of the compound of formula IV or a salt thereof:
- wherein the cancer is acute mylogenous leukemia (AML).
A method for the oral treatment of cancer comprising administering to a subject in need thereof an effective amount of the compound of formula IV or a salt thereof:
- wherein the cancer is mastocytosis.
A method for the oral treatment of cancer comprising administering to a subject in need thereof an effective amount of the compound of formula IV or a salt thereof:
- wherein the cancer is a germ cell tumor.
A method for the oral treatment of cancer comprising administering to a subject in need thereof an effective amount of the compound of formula IV or a salt thereof:
- wherein the cancer is small cell lung cancer (SCLC).
A method for the oral treatment of cancer comprising administering to a subject in need thereof an effective amount of the compound of formula IV or a salt thereof:
- wherein the cancer is melanoma.
A method for the oral treatment of cancer comprising administering to a subject in need thereof an effective amount of the compound of formula IV or a salt thereof:
- wherein the cancer is pancreatic cancer.
A method for the oral treatment of cancer comprising administering to a subject in need thereof an effective amount of the compound of formula IV or a salt thereof:
- wherein the cancer is prostate cancer.
A method for the oral treatment of cancer comprising administering to a subject in heed thereof an effective amount of the compound of formula IV or a salt thereof:
- wherein the cancer is pediatric sarcoma.
A method for the oral treatment of cancer comprising administering to a subject in need thereof an effective amount of the compound of formula IV or a salt thereof:
- wherein the cancer is resistant to STI-571.
Dependencies are inferred from the claim text.